Company intelligence / Profile preview

Sano Chemicals

Ownership: Private
Employees: ~22
Development stage: Phase 1

Overview

Sano Chemicals is a clinical-stage biotech company developing novel small molecule therapeutics for drug-resistant fungal and bacterial infections. Their lead program, Occidiofungin, targets serious fungal diseases and has entered early-stage human clinical trials. The company also develops Mutacin for antibiotic-resistant bacteria such as MRSA. They have raised $8 million in funding, hold 11 patents, and are advancing seven indications across their pipeline.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules (antifungals and antibiotics)
Industry: Biotech

Drug pipeline

3 assets

occidiofungin

2 more assets in the full pipeline.

Request access →

Partnerships

Texas A&M University/Texas A&M Innovation Office—technology licensing/commercialization partnership

Beyond the preview

Go deeper on Sano Chemicals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sano Chemicals.

Explore the full profile